Inactivated Orf virus (Parapoxvirus ovis) elicits antifibrotic activity in models of liver fibrosis

Hepatology Research

Volumn 43, Issue 5, 2013, Pages 535-546

  Nowatzky, Janina ^a,b   Knorr, Andreas ^a   Hirth Dietrich, Claudia ^a   Siegling, Angela ^a,e   Volk, Hans Dieter ^d   Limmer, Andreas ^c   Knolle, Percy ^c   Weber, Olaf ^a  

^a BAYER PHARMA AG   (Germany)

^b UNIVERSITY OF WITTEN HERDECKE   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e Dr Susanne Maier   (Austria)

Author keywords

interferon; Immunomodulation; Immunotherapy; Interleukin 10; Liver fibrosis; Parapoxvirus ovis

Indexed keywords

CARBON TETRACHLORIDE; GAMMA INTERFERON; HYDROXYPROLINE; INACTIVATED VIRUS VACCINE; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFIBROTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; AUTOPSY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MEGADOSE; EXPERIMENTAL PIG; FEMALE; HEPATITIS; HISTOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IMMUNOTHERAPY; IN VITRO STUDY; LIVER FIBROSIS; LOW DRUG DOSE; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STELLATE CELL; TISSUE CULTURE; TREATMENT DURATION; VIRUS INACTIVATION;

EID: 84876957361     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2012.01086.x     Document Type: Article

References (46)

1. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-218.
2. Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol 2011; 6: 425-456.
3. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008; 371: 838-851.
4. Powell WJ Jr, Klatskin G. Duration of survival in patients with laennec's cirrhosis. Influence of alcohol withdrawal, and possible effects of recent changes in general management of the disease. Am J Med 1968; 44: 826-832.
5. Everson GT. Management of cirrhosis due to chronic hepatitis C. J Hepatol 2005; 42 (Suppl): S65-74.
6. Issa R, Williams E, Trim N etal. Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut 2001; 48: 548-557.
7. Friedman SL, Bansal MB. Reversal of hepatic fibrosis - fact or fantasy? Hepatology 2006; 432 (Suppl 1): 582-588.
8. El Bialy SA, El Kader KF, El-Ashmawy MB. Current progress in antifibrotics. Curr Med Chem 2011; 18: 3082-3092.
9. Kisseleva T, Brenner DA. Anti-fibrotic strategies and the regression of fibrosis. Best Pract Res Clin Gastroenterol 2011; 25: 305-317.
10. Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 2011; 25: 195-206.
11. Haig DM, Mercer AA. Ovine disease. Orf. Vet Res 1998; 29: 311-326.
12. Fleming SB, McCaughan CA, Andrews AE, Nash AD, Mercer AA. A homolog of interleukin-10 is encoded by the poxvirus orf virus. J Virol 1997; 71: 4857-4861.
13. Haig DM, McInnes CJ, Thomson J, Wood A, Bunyan K, Mercer AA. The orf virus OV20.0L gene product is involved in interferon resistance and inhibits an interferon-inducible, double-stranded RNA-dependent kinase. Immunology 1998; 93: 335-340.
14. Deane D, McInnes CJ, Percival A etal. Orf virus encodes a novel secreted protein inhibitor of granulocytemacrophage colony-stimulating factor and interleukin-2. J Virol 2000; 74: 1313-1320.
15. Kruse N, Weber O. Selective induction of apoptosis in antigen-presenting cells in mice by Parapoxvirus ovis. J Virol 2001; 75: 4699-4704.
16. Weber O, Siegling A, Friebe A etal. Inactivated Parapoxvirus ovis (Orf virus) has antiviral activity against hepatitis B virus and herpes simplex virus. J Gen Virol 2003; 84: 1843-1852.
17. Milani S, Herbst H, Schuppan D, Grappone C, Heinrichs OE. Cellular sources of extracellular matrix proteins in normal and fibrotic liver: studies of gene expression by in situ hybridization. J Hepatol 1995; 22: 71-76.
18. Lortat-Jacob H, Baltzer F, Desmouliere A, Peyrol S, Grimaud JA. Lobular - but not periovular - inhibition of collagen deposition in the liver of S. mansoni infected mice using interferon-gamma. J Hepatol 1997; 26: 894-903.
19. Baroni GS, Dambrosio L, Curto P etal. Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Hepatology 1996; 23: 1189-1199.
20. Rockey DC, Maher JJ, Jamagin WR, Gabbiani G, Friedman SL. Inhibition of rat hepatic lipocyte activation in culture by interferon-gamma. Hepatology 1992; 16: 776-784.
21. Weng H, Mertens P, Gressner A, Dooley S. IFN-γ abrogates profibrotic TGF-β signaling in liver by targeting expression of inhibitory and receptor Smads. J Hepatol 2007; 46: 295-303.
22. Gurujeyalakshmi G, Giri SN. Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression. Exp Lung Res 1995; 21: 791-808.
23. Shi MN, Zheng WD, Zhan LJ, Chen ZX, Wang XZ. Effect of IL-10 on the expression of HSC growth factors in hepatic fibrosis rats. World J Gastroenterol 2005; 31: 4788-4793.
24. Shi MN, Huang YH, Zheng WD, Zhang LJ, Chen ZX, Wang XZ. Relationship between transforming growth factor beta1 and anti-fibrotic effect of interleukin-10. World J Gastroenterol 2006; 15: 2357-2362.
25. Wang SC, Ohata M, Schrum L, Rippe RA, Tsukamoto H. Expression of interleukin-10 by in vitro and in vivo activated hepatic stellate cells. J Biol Chem 1998; 273: 302-308.
26. Bhunchet E, Wake K. Role of mesenchymal cell populations in porcine serum-induced rat liver fibrosis. Hepatology 1992; 16: 1452-1473.
27. McLean EK, McLean AEM, Sutton PM. Instant cirrhosis. An improved method for producing cirrhosis of the liver in rats by simultaneous administration of carbon tetrachloride and phenobarbitone. Br J Exp Pathol 1969; 50: 502-506.
28. Prockop DJ, Udenfriend S. A specific method for the analysis of hydroxyproline in tissue and urine. Anal Biochem 1960; 1: 228-239.
29. Junqueira LC, Cossermelli W, Brentani R. Differential staining of collagens type I, II and III by Sirius Red and polarization microscopy. Arch Histol Jpn 1978; 41: 267-274.
30. Lopez-DeLeon A, Rojkind M. A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections. J Histochem Cytochem 1985; 33: 737-743.
31. Johnson SJ, Hines JE, Burt AD. Phenotypic modulation of perisinusoidal cells following acute liver injury: a quantitative analysis. Int J Exp Pathol 1992; 73: 765-772.
32. Livak KJ, Schmittgen T. Analysis of relative gene expression data using real-time quantitative PCR and the 2(Delta Delta C(T)) Method. Methods 2001; 25: 402-408.
33. Luedde T, Schwabe RF. NF-kB in the liver - linking injury, fibrosis and hepatocellular carcinoma. Nature Rev Gastroenterol Hepatol 2011; 8: 108-118.
34. Friedman SL. The cellular basis of hepatic fibrosis. N Engl J Med 1993; 25: 1828-1835.
35. Kisseleva T, Brenner DA. Hepatic stellate cells and the reversal of fibrosis. J Gastroenterol Hepatol 2006; 21 (Suppl 3): S84-87.
36. Ramadori G. The stellate cell of the liver. New insights into pathophysiology of an intriguing cell. Virchows Arch B Cell Pathol Incl Mol Pathol 1991; 61: 147-158.
37. Friebe A, Siegling A, Friederichs S, Volk HD, Weber O. Immunomodulatory effects of inactivated Parapoxvirus ovis (ORF virus) on human peripheral immune cells: induction of cytokine secretion in monocytes and Th1-like cells. J Virol 2004; 78: 9400-9411.
38. Friebe A, Friederichs S, Scholz K etal. Characterization of immunostimulatory components of Orf virus (Parapoxvirus ovis). J Gen Virol 2011; 92: 1571-1584.
39. Louis H, Van Laethem J-L, Wu W etal. Interleukin-10 controls neutrophilic infiltration, hepatocyte proliferation, and liver fibrosis induced by carbon tetrachloride in mice. Hepatology 1998; 28: 1607-1615.
40. Zhang LJ, Zheng WD, Chen YX etal. Antifibrotic effect of interleukin-10 on experimental hepatic fibrosis. Hepatogastroenterology 2007; 79: 2092-2098.
41. Phan SH. The myofibroblasts in pulmonary fibrosis. Chest 2002; 122: 2865-2895.
42. Iredale JP. Hepatic stellate cell behavior during resolution of liver injury. Semin Liver Dis 2001; 43: 427-436.
43. Herbert DR, Hölscher C, Mohrs M etal. Alternative macrophage activation is essential for survival during schistosomiasis and downmodulates T helper 1 responses and immunopathology. Immunity 2004; 20: 623-635.
44. Odegaard JI, Ricardo-Gonzalez RR, Red Eagle A etal. Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab 2008; 7: 496-507.
45. Baffy G. Kupffer cells in non-alcoholic fatty liver disease: the emerging view. Hepatology 2009; 51: 212-223.
46. Allison RD, Katsounas A, Koziol DE etal. Association of interleukin-15-induced peripheral immune activation with hepatic stellate cell activation in persons coinfected with hepatitis C virus and HIV. J Infect Dis 2009; 200: 619-623.